RFK Jr. reportedly urges FDA leniency on popular, unproven peptide drugs
Reports indicate that Robert F. Kennedy Jr. has proposed that federal regulators take a lax approach toward popular peptide treatments, despite FDA scientists warning that these substances lack established safety and efficacy data. This policy shift could significantly impact the regulatory landscape for wellness drugs, raising public health concerns over widespread unverified usage.
Source: Ars Technica